Zura Bio Ltd (ZURA)
5.33
+0.06
(+1.14%)
USD |
NASDAQ |
Jun 03, 10:46
Zura Bio Enterprise Value: 259.00M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 259.00M |
| May 30, 2024 | 265.37M |
| May 29, 2024 | 246.90M |
| May 28, 2024 | 257.73M |
| May 24, 2024 | 273.01M |
| May 23, 2024 | 282.56M |
| May 22, 2024 | 274.92M |
| May 21, 2024 | 273.65M |
| May 20, 2024 | 304.85M |
| May 17, 2024 | 308.67M |
| May 16, 2024 | 305.49M |
| May 15, 2024 | 253.91M |
| May 14, 2024 | 252.00M |
| May 13, 2024 | 228.43M |
| May 10, 2024 | 221.43M |
| May 09, 2024 | 216.33M |
| May 08, 2024 | 216.94M |
| May 07, 2024 | 212.58M |
| May 06, 2024 | 215.70M |
| May 03, 2024 | 211.33M |
| May 02, 2024 | 195.13M |
| May 01, 2024 | 182.04M |
| April 30, 2024 | 189.52M |
| April 29, 2024 | 212.58M |
| April 26, 2024 | 198.24M |
| Date | Value |
|---|---|
| April 25, 2024 | 149.01M |
| April 24, 2024 | 129.69M |
| April 23, 2024 | 140.28M |
| April 22, 2024 | 129.69M |
| April 19, 2024 | 67.68M |
| April 18, 2024 | 84.25M |
| April 17, 2024 | 59.84M |
| April 16, 2024 | 55.91M |
| April 15, 2024 | 60.27M |
| April 12, 2024 | 69.86M |
| April 11, 2024 | 48.50M |
| April 10, 2024 | 44.58M |
| April 09, 2024 | 44.14M |
| April 08, 2024 | 45.01M |
| April 05, 2024 | 42.40M |
| April 04, 2024 | 49.81M |
| April 03, 2024 | 51.12M |
| April 02, 2024 | 51.12M |
| April 01, 2024 | 47.63M |
| March 28, 2024 | 32.45M |
| March 27, 2024 | 21.55M |
| March 26, 2024 | 18.94M |
| March 25, 2024 | 25.04M |
| March 22, 2024 | 9.782M |
| March 21, 2024 | 46.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
9.782M
Minimum
Mar 22 2024
895.35M
Maximum
Mar 23 2023
173.36M
Average
159.22M
Median
Enterprise Value Benchmarks
| GT Biopharma Inc | -4.493M |
| Outlook Therapeutics Inc | 162.76M |
| IMAC Holdings Inc | 3.232M |
| Nkarta Inc | 41.08M |
| 180 Life Sciences Corp | 1.638M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.747M |
| Total Expenses (Quarterly) | 8.379M |
| EPS Diluted (Quarterly) | -0.02 |
| Earnings Yield | -31.03% |